This article focuses on the development of 2 major adverse drug events associated with some fluoroquinolone antimicrobial agents, specifically cardiac and glycemic effects. Cardiac dysfunction, including corrected QT (QTc) interval prolongation and torsades de pointes, has been linked to the administration of fluoroquinolones. The first indication of QTc prolongation was reportedwith sparfloxacin, and since that time, it has been associated with a number of other fluoroquinolones, leading to the assumption that this is a general class effect. Fluoroquinolone-associated effects on cardiac conduction appear more likely to occur in patients with underlying cardiac diseases, those with electrolyte abnormalities, and those coadministered antiarrhythmics and other QTc-prolonging drugs. Some fluoroquinolone agents have also been associated with alterations in glycemic control. Hypoglycemia and hyperglycemia have been reported with many of the currently available agents. Risk factors for aberrations in glucose homeostasis include noninsulindependent diabetes mellitus, increased age, impaired renal function, and the concomitant use of oral hypoglycemic agents. The widespread use of fluoroquinolones highlights the need for clinicians to consider predisposed populations and use caution when selecting antimicrobial therapies.
Get full access to this article
View all access options for this article.
References
1.
1. Paladino JA. Is more than one quinolone needed in clinical practice? Ann Pharmacother. 2001;35:1085-1095.
2.
2. Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation 8-methoxy fluoroquinolone. J Resp Dis. 1999;20:S70-S76.
3.
3. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis. 1999;28:352-364.
4.
4. Owens RC. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy. 2001;21(3):301-319.
5.
5. Ball P. Quinolone-inducted QT interval prolongation: a notsounexpected class effect. J Antimicrob Chemother. 2000;45:557-559.
6.
6. Shah RR. The significance of QT interval in drug development. J Clin Pharmacol. 2002;54:188-202.
7.
7. Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother. 2002;49:593-596.
8.
8. Committee for Proprietary Medicinal Products. Points to Consider: The Assessment of the Potential for QTc Interval Prolongation by Non-Cardiovascular Medicinal Products. London: The European Agency for Evaluation of Medicinal Product; 1997.
9.
9. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy. 2001;21(10S):253S-272S.
10.
10. Heinemann SH. Pharmacology review: effects of fluoroquinolones on HERG channels, stably expressed in HEK293 cells (Bayer report no. R 7854; study no. 72064976). Available at: http://www.fda.gov/cder/foi/nda/2001/21277_Avelox_pharmr.pdf. Accessed February 28, 2003.
11.
11. AndersonME, Mazur A, Yang T, et al. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther. 2001;296:806-810.
12.
12. Kang J, Wang J, Chen XL, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol. 2001;59:122-126.
14. Noel GJ, Abels R, Minton N, et al. Effect of three fluoroquinolones (FQs) on QTc intervals in healthy volunteers [abstract]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 2001:24-24.
16. Bertino JS, Owens RC, Carnes TD, et al. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis. 2002;34:861-863.
17.
17. Iannini PB, Circiumaru I. Gatifloxacin-induced QTc prolongation and ventricular tachycardia. Pharmacotherapy. 2001;21: 361-362.
18.
18. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy. 2001;21(12):1468-1472.
19.
19. Iannini PB, Circiumaru J, Byazrova E, et al. QTc prolongation associated with levofloxacin. Br Med J. 2001;7277:46-47.
20.
20. Cipro [package insert]. West Haven, Conn: Bayer Corporation; 2002.
21.
21. Owens RC, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy. 2002;22(5):663-672.
22.
22. Schaffer D, Singer S, Korvick J. Macrolide and fluoroquinolone associated torsades de pointes: a review of the FDA adverse event reported system [abstract]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 2001:20-20.
26. Menzies DJ, Dorsainvil PA, Dunha BA, et al. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med. 2002;113:232-234.
27.
27. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. Goodman & Gilman’s the Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996: 1487-1517.
28.
28. Maeda N, Tamagawa T, Niki I, et al. Increase in insulin release from rat pancreas islets by quinolone antibiotics. Br J Pharmacol. 1996;117(2):372-376.
30. Fraser AG, Harrower AD. Convulsions and hyperglycaemia associated with nalidixic acid. Br Med J. 1977;2(6101):1518-1518.
31.
31. Jick SS, Jick H, Dean AD. A follow-up safety study of ciprofloxacin users. Pharmacotherapy. 1993;13(5):461-464.
32.
32. Roberge RJ, Kaplan R, Frank R, et al. Glyburide-ciprofloxacin interaction with resistant hypoglycemia. Ann Emerg Med. 2000;36:160-163.
33.
33. WhitelyM, Worlding J, Patel S, et al. Hypoglycemia in a diabetic patient, associate with ciprofloxacin therapy [case report]. Pract Diabetes. 1993;10:35.
34.
34. US Food and Drug Administration, Center for Drug Evaluation and Research. New drug approval packages—Levaquin/ Levofloxacin (R. W. Johnson Pharmaceuticals application no 020634, parts 1, 2, 3, & 4). Available at: http://www.fda/gov/cder/foi/nda/index96.htm. Accessed March 1, 2003.
36. US Food and Drug Administration, Center for Drug Evaluation andResearch. Data taken for review of the safety of moxifloxacin hydrochloride from the original NDA as found in parts 4 and 5. Available at: http://www.fda.gov/cder/nda/99/21_085_Avelox_medr_P1. Accessed October 27, 2002.
37.
37. Grasela DM. Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clin Infect Dis.2000;31(suppl):S51-S58.
38.
38. Gajjar DA, LaCreta FP, Uderman HD, et al. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy. 2000;20(suppl):49S-58S.
39.
39. Gajjar DA, LaCreta FP, Kollia GD, et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with non-insulin dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy. 2000;20(suppl):76S-86S.
40.
40. GraselaDM, LaCreta FP, Kollia GD, et al. Lack of effect ofmultiple-dose gatifloxacin (GAT) on oral glucose tolerance (OGTT), glucose and insulin homeostasis, and glyburide pharmacokinetics (PK) in type II non-insulin dependent diabetes mellitus(NIDDM) [abstract]. In: Proceedings and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society forMicrobiology; 1999:11-11.
41.
41. Baker SE, Hang Hangi MC. Possible gatifloxacin-induced hypoglycemia. Ann Pharmacother. 2002;36:1722-1726.
42.
42. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 2003;73:292-303.
